Ultrahigh performance liquid chromatography (UHPLC) uses small stationary-phase particle size (<2 μm) and high pressure in order to achieve rapid and efficient separations. The speed and high resolution of this method has made it a valuable tool for analyzing the complex glycosylation patterns found in post-translationally modified proteins. This article highlights the differences between UHPLC […]
The integration of ligand-binding assay and LC–MS/MS (immunocapture-LC–MS) has unleashed the combined advantages of both powerful techniques for addressing the ever increasing bioanalytical challenges for biotherapeutics and biomarker assays. The highly specific, selective and sensitive characteristics of the immunocapture-LC–MS-based assays have enabled the determination of biotherapeutics and biomarkers in biomatrices with ease of method development,
Aim: Comprehensive development of a method for SPE extraction of antisense phosphorothioate oligonucleotide and its metabolites and their determination with the use of UHPLC. Results: Polymer-based adsorbent and high percentage of methanol in elution solvent provided high recoveries compared with silica-based octadecyl cartridge. As to the type and concentration of ion pair reagent and organic
The 12th WRIB held in Philadelphia, USA in April 2018. It drew over 900 professionals representing large Pharmas, Biotechs, Contract Research Organizations and multiple regulatory agencies from around the world, from the global bioanalytical community. Bioanalysis and Bioanalysis Zone are very proud to be supporting the WRIB Poster Awards again this year, and we feature
Since 2014, the European Bioanalysis Forum organizes a Young Scientist Symposium. The meeting format was created to provide development opportunities for young scientists to engage in international discussions. Creating a peer community of young scientists has been a proven recipe to lower the threshold and promote engagement in this community of young talents. At the
VOLUME 10, ISSUE 20 / OCTOBER 2018 Conference Report OCTOBER 2018 Feedback from the fourth European Bioanalysis Forum Young Scientist Symposium Sofie Velghe, Laura Mercolini, Ryan McDonagh, Cara Maguire, Farjana Mahammed, Richard Lucey, Ariane Kahnt, Godknows Hlatshwayo, Jörg Faber & Philip Timmerman Pages:1631–1634 Published Online:24 October 2018 Buy PDF/ $200 Special Feature OCTOBER 2018 Workshop on Recent Issues in
OCTOBER 2018 | VOL. 10, NO. 20 Read More »
Synthetic cannabinoids are a new class of chemical drugs capable of modifying human behavior. These products do not contain cannabis, but produce similar effects after consumption. The fact that they are easily accessed, and are many times considered to be harmless, justifies their widespread use among young people. This fact, together with the difficulty in
Aim: Co-metabolism between a human host and the gastrointestinal microbiota generates many small phenolic molecules such as 3-hydroxy-3-(3-hydroxyphenyl)propanoic acid (3,3-HPHPA), which are reported to be elevated in schizophrenia and autism. Characterization of these chemicals, however, has been limited by analytic challenges. Methodology/results: We applied HPLC to separate and quantify over 50 analytes, including multiple structural
Aim: To develop an LC–MS/MS assay to quantitate well-tolerated substrates; midazolam (CYP3A), omeprazole (CYP2C19), dextromethorphan (CYP2D6), losartan (CYP2C9) and their respective metabolites’ concentrations in plasma samples. Patients & methods: A solid-phase extraction method was optimized to extract analytes of interest simultaneously from human plasma samples. The assay analyzed plasma samples collected from patients who received
Aim: The combination of levodopa with carbidopa has been used for treatment of Parkinson’s disease being an important therapy in dopamine level control in the brain. Both are very polar compounds becoming a challenge for analysis by LC–MS/MS.Materials & methods: In this work, it was developed and validated a sensitive bioanalytical method by UHPLC–MS/MS for